NCT04266249 2026-03-02
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT07053085 2026-02-27
A Study of Surgery and Radiotherapy in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02624973 2026-02-12
PETREMAC
Haukeland University Hospital
Phase 2 Active not recruiting
NCT01796197 2026-02-05
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06092892 2025-12-10
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT02883062 2025-10-16
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02326974 2025-03-05
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT01234532 2022-05-03
0927GCC
University of Maryland, Baltimore
Phase 2 Terminated
NCT02953184 2017-12-29
Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy
Jilin University
Phase 2 Unknown
NCT02673268 2017-10-12
MARCI
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT01167192 2016-12-30
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer
Washington University School of Medicine
Phase 2 Terminated